Context: Infections by multiresistant bacteria increase the risk of therapeutic failure, increasing hospital stay, costs and mortality. This determines the use of more expensive antibacterials with a broader spectrum, which leads to a high consumption at the hospital level, which increases bacterial resistance. Aims: To characterize the consumption of antibacterials in three hospitals in Santiago de Cuba. Methods: A descriptive and cross-sectional study of consumption was carried out. The consumed units, anatomical, therapeutic, and chemical classification, route of administration and price were analyzed for each antimicrobial. The defined daily dose (DDD)/100 beds/day and the cost of antibacterials for systemic use were determined. Descriptive statistics were used. Results: The most used antibacterial in both years (2019 and 2020) was ceftriaxone (12.6% and 26.9%). The most used group was J01D (39.5% and 44.8%), mainly parenteral via. In 2019 they presented higher DDD/100 beds/day: gentamicin (38.74 in the General Hospital and 20.20 in the Maternal Hospital) and ciprofloxacin (31.51 in the General Hospital and 15.00 in the Oncology Hospital); and in 2020 it was cefazolin (41.42 in General Hospital), ciprofloxacin (17.73 in Oncology) and gentamicin (26.99 in Maternal). The highest total costs were for ciprofloxacin and ceftriaxone. Conclusions: The increase in consumption evidenced the need to update therapeutic policies and validation of prescriptions for this group of drugs.

Context: Immunotherapy, by directing the immune response against tumor cells, complements the oncological therapy along with conventional treatments. Thus, the monoclonal antibody nimotuzumab blocks the binding of epidermal growth factor to its receptor, interfering with cell proliferation in epithelial tumors, such as those of the head and neck. Aims: To evaluate the safety of nimotuzumab after concluded the clinical trials in epithelial tumors of the head and neck, analyzing the relation with the therapeutic compliance for the patients. Methods: A retrospective descriptive study was carried out, characterizing nine patients with epithelial tumors of the head and neck, who continued to use nimotuzumab after concluding clinical trials; and evaluating adverse effects according to severity, intensity, causality, and frequency, thus establishing the safety of this medicine. The compliance of nimotuzumab therapy was analyzed, by reviewing the administration intervals to the received doses. A descriptive statistical analysis was performed. Results: In the studied sample men predominated (eight patients: 88.89%), without significance differences in age and race. All were diagnostic with epidermal carcinomas, predominated the good differentiated (six patients: 66.67%). Five adverse effects were detected in two old patients (all not serious, light or moderate, and possible or probable, occasional or frequent), evaluating to nimotuzumab as safe medication. There was inadequate therapeutic compliance to treatment, not relation with the presented adverse effects. Conclusions: Nimotuzumab represented a safe drug after concluded the clinical trials in patients with epithelial tumors of the head and neck, without relation with the existed inadequate therapeutic compliance.

La vaginosis bacteriana es un trastorno del tracto reproductivo muy común a nivel mundial en mujeres en edad fértil y figura entre las cinco categorías principales de atención médica en consultas ginecológicas. Se realizó un estudio de intervención en 200 gestantes con vaginosis bacteriana desde la Consulta de Ginecobstetricia del Policlínico “Julian Grimau” en el municipio Santiago de Cuba, en el periodo de julio a diciembre de 2020. Se definieron criterios de inclusión, exclusión y salida; siendo caracterizadas las gestantes mediante variables biosociales, clínicas y farmacoterapéuticas. Se aplicó un cuestionario para determinar el nivel de conocimiento de la enfermedad y el tratamiento antes y después de la intervención. Predominaron las gestantes en el grupo de edad de 25-29 años (29 %), con nivel escolar preuniversitario (55 %), fumadoras (9 %), cuya edad de inicio de la primera relación sexual fue de 15-19 años (80 %) y que tuvieron de 4-6 parejas sexuales (56 %). Prevalecieron aquellas con antecedentes de alergia (41.5 %), seguidas de hipertensión arterial (HTA) con (23.7 %). En cuanto a las farmacoterapéuticas hubo predominio de aquellas que consumieron de 5-9 medicamentos (81 %) y en la utilización de los grupos farmacológicos se destacaron los antimicrobianos y las vitaminas (100 %). El nivel de conocimiento de la enfermedad antes de la intervención resultó bajo (61,5 %) y el del tratamiento fue medio mayoritariamente (41,5 %). Después de la intervención se constató un incremento en el nivel de conocimientos de las pacientes, perdurando en el tiempo.